39
Participants
Start Date
July 12, 2022
Primary Completion Date
January 31, 2024
Study Completion Date
February 29, 2024
HAIC
After successful percutaneous hepatic artery cannulation, superior mesenteric arteriogram and hepatic arteriogram were performed, and after confirming that the subjects were eligible for enrollment according to the results, the hepatic artery was cannulated to the predetermined position. The catheter was connected to a syringe pump in the ward for continuous pumping of drugs.
Fruquintinib
3mg, qd, po, 21 days for a cycle, Suspend medication on the day of HAIC
Tislelizumab
200mg, ivgtt, d1, 21 days for a cycle
Raltitrexed
2 mg/m2, hepatic artery infusion for 15 min, d1, 4-6 Cycles
Oxaliplatin
85 mg/m2, hepatic artery infusion for 2 h, d1, 4-6 Cycles
Irinotecan
120mg/m2, hepatic artery perfusion for 30-90min, d1, 4-6 Cycles
Fudan University Shanghai Cancer Center, Shanghai
Fudan University
OTHER